Bristol Myers Squibb (BMY) reported a substantial Q3 2025 revenue of $12.2 billion, driven by newer products like Opdivo and Eliquis, while anticipating a 15-17% decline in legacy product revenues due to patent expirations. The company projects continued growth in Opdivo sales, expected to rise in the high single-digit to low double-digit range by 2025. Despite facing challenges from generics and declining legacy revenues, BMY remains a competitive player in the pharmaceutical sector, bolstered by an attractive dividend yield of 4.54% and a commitment to innovation.
“Bristol Myers Squibb · has revenue growth from · newer products · yes”
“Bristol Myers Squibb · has revenue decline from · legacy products · yes”
“Bristol Myers Squibb · is focused on · discovering, developing and delivering transformational therapies · oncology, hematology, immunology, cardiovascular, neuroscience and other serious diseases”
“Revlimid · was · Bristol Myers Squibb's best-selling medicine · true”
“Motley Fool Stock Advisor analyst team · believes · Bristol Myers Squibb · is not one of the 10 best stocks to buy”
“Bristol Myers Squibb · is focused on · discovering, developing and delivering transformational therapies · across oncology, hematology, immunology, cardiovascular, neuroscience and other serious diseases”
“Bristol Myers Squibb · has a growth portfolio that comprises drugs like · Opdivo, Opdivo Qvantig, Orencia and others · for various serious diseases”
“Bristol Myers Squibb · expects global Opdivo sales to increase · in the high single-digit to low double-digit range · in 2025”
“Bristol Myers Squibb · expects the legacy portfolio to decline · approximately 15-17% in 2025”
“BMY’s dividend yield · is higher than · AMGN’s dividend yield · 4.54% vs 2.86%”
“Both AMGN and BMY · currently carry · a Zacks Rank #3 · (Hold)”
“Bristol Myers Squibb · is · a top pharmaceutical business · true”
.svg&width=160)
